The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 28, 2023

Filed:

Nov. 14, 2016
Applicant:

Pds Biotechnology Corporation, North Brunswick, NJ (US);

Inventors:

Frank Bedu-Addo, Carmel, IN (US);

Greg Conn, Madrid, ES;

Siva K. Gandhapudi, Blue Ash, OH (US);

Martin Ward, Lexington, KY (US);

Jerold Woodward, Lexington, KY (US);

Assignee:

PDS Biotechnology Corporation, North Brunswick, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 35/14 (2015.01); C12N 5/0784 (2010.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 35/14 (2013.01); A61K 39/00117 (2018.08); A61K 39/12 (2013.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); C12N 5/0639 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/57 (2013.01); A61K 2039/572 (2013.01); A61K 2039/585 (2013.01); C12N 2710/20034 (2013.01);
Abstract

The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+ and CD4+ T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.


Find Patent Forward Citations

Loading…